1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Merck Calls It Quits On Anacetrapib

 
• By Mary Jo Laffler and Emily Hayes

Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.

Stop barrier

Merck & Co. Inc. is making the prudent choice in opting not to pursue regulatory approval for the CETP inhibitor anacetrapib, avoiding the commercial quagmire of the cholesterol market that has hindered uptake of the PCSK9 inhibitor class.

"The decision follows a thorough review of the clinical profile of anacetrapib, including discussions with external experts," the firm said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Another Baxdrostat Success Takes Pressure Off AstraZeneca

 
• By Andrew McConaghie

A second Phase III win for the investigational hypertension drug will help convince analysts that AstraZeneca can reach $80bn sales by 2030, but more pivotal trial successes will be needed over the next few years.

Amgen Joins Direct-To-Patient Rush With Repatha Program

 
• By Alaric DeArment

The drugmaker said it would make the PCSK9 inhibitor available to patients directly, just days after announcing positive data in patients without histories of strokes or heart attacks.

Primary-Prevention Data Should Boost Uptake Of Amgen’s Repatha

 
• By Alaric DeArment

The drugmaker announced positive results from a 12,000-patient Phase III study showing Repatha is effective in patients who have not experienced a CV event.

Merck’s Positive Winrevair Data Expected To Drive PAH Market Growth

 
• By Alaric DeArment

The data showed a significant reduction in worsening of disease conditions among recently diagnosed patients in the Phase III HYPERION trial.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.